Overview

The Government of India, represented by Union Minister of Health and Family Welfare Shri Jagat Prakash Nadda, called for a shift toward patient‑centric innovation in the life‑sciences sector, emphasizing that true success lies in moving discoveries from the laboratory bench to bedside care. He highlighted the Ayushman Bharat PM‑JAY scheme, which now provides a Rs 5 lakh annual health cover to every citizen aged 70 years and above, as an example of public‑purpose‑driven bio‑economy achievements.

Bharat Life Sciences Award (BLSA) Launch and Grants

The inaugural Bharat Life Sciences Award, a biennial initiative jointly organized by the Federation of Indian Chambers of Commerce & Industry (FICCI) and powered by Eli Lilly and Company (India), announced its first cohort of awardees at Vigyan Bhawan. The award is backed by a total grant pool of Rs 7 crore, which was allocated after receiving more than 500 applications. An independent evaluation panel, advised by Grant Thornton Bharat LLP, assessed submissions on scientific excellence, innovation, evidence, relevance to India, and potential impact.

Awardees and Recognitions

  • Ramanujan Arogya Udaan Samman (Young Scientist): Dr Vamsee Mallajosyula, National Centre for Biological Sciences (TIFR); runner‑up Dr Bharti Bhatia, Translational Health Science and Technology Institute.
  • Charaka Arogya Samman (Innovation for Unmet Patient Needs): Pacify Medical Technologies.
  • Sushruta Arogya Samman (Translational and Clinical Advancement): Bharat Serums and Vaccines (BSV‑Mankind).
  • Nalanda Arogya Vigyan Samman (Institute of Scientific Excellence): BRIC‑National Institute of Biomedical Genomics; runner‑up LV Prasad Eye Institute.
  • Jivaka Arogya Navpravartan Gaurav (Startup and Academic Innovator): Sciverse Solutions.
  • Sarabhai Arogya Drishti Gaurav (Promoting Scientific Ecosystems): Dr Ratnesh Jain, Institute of Chemical Technology, Mumbai.

Policy and Industry Perspectives

During the accompanying Innovation Summit, which attracted over 50 senior government officials, more than 100 chief executives and approximately 1,200 delegates, several officials underscored systemic challenges and opportunities:

  • Manoj Joshi, Secretary, Department of Pharmaceuticals, praised the recent rise in biologics manufacturing capacity but warned that India remains heavily dependent on European suppliers for critical inputs such as media, resins, cell lines, and enzymes. He noted that the Biopharma Shakti scheme will soon extend support across the entire value chain, including regulatory approvals abroad and capacity expansion.
  • Rajeev Singh Raghuvanshi, Drugs Controller General of India, outlined three expectations for innovators: robust innovation, collaborative partnerships, and early regulatory dialogue. He urged that a regulatory strategy be embedded from the outset, citing the heat‑stable, nasal, and mRNA COVID‑19 vaccines as examples of rapid innovation.
  • David A. Ricks, Chair and CEO of Eli Lilly, affirmed the award’s role in recognizing talent, fostering collaboration, and accelerating ideas toward real‑world health impact.
  • Pankaj Patel, Past President of FICCI and Chairman of Zydus Lifesciences, highlighted that India bears 15 % of the global disease burden yet conducts only 4 % of global clinical trials. He called for R&D spending to rise from the current ~5 % of sales to 8‑10 % and urged the government to reinstate the 200 % R&D tax deduction, with industry matching the incentive rupee‑for‑rupee. He also advocated for predictable regulatory timelines, expedited pathways for breakthrough therapies, and for the government to act as the first customer for domestically developed innovations.
  • Gobardhan Das, Member, NITI Aayog, stressed the need for a deeper pipeline of new vaccines and medicines and emphasized the importance of academia‑industry collaboration, especially leveraging India’s artificial‑intelligence capabilities.

Institutional Support and Partnerships

The BLSA is convened in consultation with the Office of the Principal Scientific Adviser, the Department of Pharmaceuticals, Startup India, DPIIT, ICMR, BIRAC, Invest India, and is supported by bodies such as the Indian Drug Manufacturers’ Association, Indian Medical Parliamentarians’ Forum, Indian Pharmaceutical Alliance, Indian Vaccine Manufacturers Association, Organisation of Pharmaceutical Producers of India, U.S.–India Business Council, and U.S.–India Strategic Partnership Forum.

Significance

The award and its accompanying summit aim to catalyze a transition for India from a large‑scale manufacturing hub to a global innovation hub in life sciences, aligning scientific talent with public‑purpose objectives and encouraging higher private R&D investment, regulatory facilitation, and ecosystem collaboration.